Skip to main content
SpringerLink
Log in

Kardio-Onkologie

  • Chapter
  • First Online:
Klinische Kardiologie

Part of the book series: Springer Reference Medizin ((SRM))

  • 1338 Accesses

Zusammenfassung

Die onkologische Kardiologie beschäftigt sich mit der Prävention, Frühdiagnose und Behandlung von kardiotoxischen Nebenwirkungen der modernen, multimodalen Tumortherapie. Zur Tumortherapie gehören neben der Operation, die Strahlentherapie, die klassische oder konventionelle Chemotherapie, die zielgerichtete Therapie sowie die Immuntherapie. Das Nebenwirkungsschema dieser Therapien ist komplex und zum Teil unvollständig charakterisiert. Darüber hinaus werden bis zu 30 neue Therapien pro Jahr zugelassen, was eine große Herausforderung an das Gebiet der onkologischen Kardiologie darstellt. In dem aktuellen Kapitel sollen die einzelnen Modalitäten der Tumortherapie hinsichtlich ihrer kardiovaskulären Nebenwirkungen vorgestellt bzw. mögliche diagnostische und therapeutische Algorithmen beleuchtet werden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 239.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Literatur

  • Al-Kindi SG, Oliveira GH (2016) Prevalence of preexisting cardiovascular disease in patients with different types of cancer: the unmet need for onco-cardiology. Mayo Clin Proc 91(1):81–83

    Article  PubMed  Google Scholar 

  • Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, Dent S, Douglas PS, Durand JB, Ewer M, Fabian C, Hudson M, Jessup M, Jones LW, Ky B, Mayer EL, Moslehi J, Oeffinger K, Ray K, Ruddy K, Lenihan D (2017) Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 35(8):893–911

    Article  PubMed  Google Scholar 

  • Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR Jr, das Dores Cruz F, Brandao SMG, Rigaud VOC, Higuchi-Dos-Santos MH, Hajjar LA, Filho RK, Hoff PM, Sahade M, Ferrari MSM, de Paula Costa RL, Mano MS, Cruz CBBV, Abduch MC, Alves MSL, Guimaraes GV, Issa VS, Bittencourt MS, Bocchi EA (2018) Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial. J Am Coll Cardiol 71(20):2281–2290

    Article  PubMed  Google Scholar 

  • Brown JR, Moslehi J, O’Brien S, Ghia P, Hillmen P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Kipps TJ, Coutre S, Dilhuydy MS, Cramer P, Tedeschi A, Jaeger U, Dreyling M, Byrd JC, Howes A, Todd M, Vermeulen J, James DF, Clow F, Styles L, Valentino R, Wildgust M, Mahler M, Burger JA (2017) Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica 102(10):1796–1805

    Article  PubMed  PubMed Central  Google Scholar 

  • Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, Cauquil C, Chanson P, Collins M, Durrbach A, Ederhy S, Feuillet S, Francois H, Lazarovici J, Le Pavec J, De Martin E, Mateus C, Michot JM, Samuel D, Soria JC, Robert C, Eggermont A, Marabelle A (2016) Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 27(4):559–574

    Article  PubMed  Google Scholar 

  • Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Juni P, Lettino M, Marx N, Mellbin LG, Ostgren CJ, Rocca B, Roffi M, Sattar N, Seferovic PM, Sousa-Uva M, Valensi P, Wheeler DC, E. S. C. S. D. Group (2020) 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 41(2):255–323

    Article  PubMed  Google Scholar 

  • Cuomo JR, Sharma GK, Conger PD, Weintraub NL (2016) Novel concepts in radiation-induced cardiovascular disease. World J Cardiol 8(9):504–519

    Article  PubMed  PubMed Central  Google Scholar 

  • D’Souza M, Svane IM, Gislason G, Schou M (2021) Immune check point inhibitors are associated with a spectrum of cardiac events in patients with cancer. Eur Heart J 42(16):1636

    Article  PubMed  Google Scholar 

  • Gernaat SAM, Ho PJ, Rijnberg N, Emaus MJ, Baak LM, Hartman M, Grobbee DE, Verkooijen HM (2017) Risk of death from cardiovascular disease following breast cancer: a systematic review. Breast Cancer Res Treat 164(3):537–555

    Article  PubMed  PubMed Central  Google Scholar 

  • Ghosh AK, Chen DH, Guha A, Mackenzie S, Walker JM, Roddie C (2020) CAR T cell therapy-related cardiovascular outcomes and management systemic disease or direct cardiotoxicity? Jacc: Cardiooncology 2(1):98–109

    Google Scholar 

  • Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, von Knobelsdorff-Brenkenhoff F, Bratland A, Storas TH, Hagve TA, Rosjo H, Steine K, Geisler J, Omland T (2016) Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 37(21):1671–1680

    Article  PubMed  PubMed Central  Google Scholar 

  • Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, Lopez JA, Chen J, Chung D, Harju-Baker S, Cherian S, Chen X, Riddell SR, Maloney DG, Turtle CJ (2017) Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130(21):2295–2306

    Article  PubMed  PubMed Central  Google Scholar 

  • Jackson HJ, Rafiq S, Brentjens RJ (2016) Driving CAR T-cells forward. Nat Rev Clin Oncol 13(6):370–383

    Article  PubMed  PubMed Central  Google Scholar 

  • Lu HM, Cash E, Chen MH, Chin L, Manning WJ, Harris J, Bornstein B (2000) Reduction of cardiac volume in left-breast treatment fields by respiratory maneuvers: a CT study. Int J Radiat Oncol Biol Phys 47(4):895–904

    Article  PubMed  Google Scholar 

  • Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J (2018) Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol 19(9):e447–e458

    Article  PubMed  Google Scholar 

  • Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O, E. S. C. S. D. Group (2020) 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41(1):111–188

    Article  PubMed  Google Scholar 

  • Michel L, Rassaf T, Totzeck M (2018) Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity. J Thorac Dis 10(Suppl 35):S4282–S4295

    Article  PubMed  PubMed Central  Google Scholar 

  • Michel L, Mincu RI, Mahabadi AA, Settelmeier S, Al-Rashid F, Rassaf T, Totzeck M (2020) Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. Eur J Heart Fail 22(2):350–361

    Article  PubMed  Google Scholar 

  • Minckwitz G von, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J, Committee AS, Investigators (2017) Adjuvant Pertuzumab and Trastuzumab in early HER2-positive breast cancer. N Engl J Med 377(2):122–131

    Google Scholar 

  • Mincu RI, Mahabadi AA, Michel L, Mrotzek SM, Schadendorf D, Rassaf T, Totzeck M (2019) Cardiovascular adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis. JAMA Netw Open 2(8):e198890

    Article  PubMed  PubMed Central  Google Scholar 

  • Moslehi JJ (2016) Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med 375(15):1457–1467

    Article  PubMed  Google Scholar 

  • Park JH, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, Roshal M, Maslak P, Davila M, Brentjens RJ, Sadelain M (2018) Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 378(5):449–459

    Article  PubMed  PubMed Central  Google Scholar 

  • Rassaf T, Heusch G (2021) The west German heart and vascular Center at University Medicine Essen. Eur Heart J 42(10):963–964

    Article  PubMed  Google Scholar 

  • Rassaf T, Totzeck M, Backs J, Bokemeyer C, Hallek M, Hilfiker-Kleiner D, Hochhaus A, Lüftner D, Müller OJ, Neudorf U, Pfister R, von Haehling S, Lehmann LH, Bauersachs J (2020) Onco-cardiology: consensus paper of the German cardiac society, the German society for pediatric cardiology and congenital heart defects and the German society for hematology and medical oncology. Clin Res Cardiol 109(10):1197–1222

    Article  PubMed  PubMed Central  Google Scholar 

  • Rochette L, Guenancia C, Gudjoncik A, Hachet O, Zeller M, Cottin Y, Vergely C (2015) Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms. Trends Pharmacol Sci 36(6):326–348

    Article  PubMed  Google Scholar 

  • Saleh Y, Abdelkarim O, Herzallah K, Abela GS (2020) Anthracycline-induced cardiotoxicity: mechanisms of action, incidence, risk factors, prevention, and treatment. Heart Fail Rev 26(5):1159–1173

    Article  Google Scholar 

  • Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J, Hurwitz H (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99(16):1232–1239

    Article  PubMed  Google Scholar 

  • Taylor C, Correa C, Duane FK, Aznar MC, Anderson SJ, Bergh J, Dodwell D, Ewertz M, Gray R, Jagsi R, Pierce L, Pritchard KI, Swain S, Wang Z, Wang Y, Whelan T, Peto R, McGale P (2017) Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials. J Clin Oncol 35(15):1641–1649

    Article  PubMed  PubMed Central  Google Scholar 

  • Totzeck M, Schuler M, Stuschke M, Heusch G, Rassaf T (2019) Cardio-oncology – strategies for management of cancer-therapy related cardiovascular disease. Int J Cardiol 280:163–175

    Article  PubMed  Google Scholar 

  • Totzeck M, Siebermair J, Rassaf T, Rischpler C (2020) Cardiac fibroblast activation detected by positron emission tomography/computed tomography as a possible sign of cardiotoxicity. Eur Heart J 41(9):1060

    Article  PubMed  Google Scholar 

  • Wang DY, Okoye GD, Neilan TG, Johnson DB, Moslehi JJ (2017) Cardiovascular toxicities associated with cancer immunotherapies. Curr Cardiol Rep 19(3):21

    Article  PubMed  PubMed Central  Google Scholar 

  • Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I, E. S. C. S. D. Group (2018) 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 39(33):3021–3104

    Article  PubMed  Google Scholar 

  • Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM, E. S. C. S. D. Group (2016) 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37(36):2768–2801

    Article  PubMed  Google Scholar 

  • Zamorano JL, Gottfridsson C, Asteggiano R, Atar D, Badimon L, Bax JJ, Cardinale D, Cardone A, Feijen EAM, Ferdinandy P, Lopez-Fernandez T, Gale CP, Maduro JH, Moslehi J, Omland T, Plana Gomez JC, Scott J, Suter TM, Minotti G (2020) The cancer patient and cardiology. Eur J Heart Fail 22(12):2290–2309

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Kardiologie und Angiologie, Westdeutsches Herz- und Gefäßzentrum, Universitätsklinikum Essen, Essen, Deutschland

    Tienush Rassaf

Authors
  1. Tienush Rassaf
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tienush Rassaf .

Editor information

Editors and Affiliations

  1. Medizinische Klinik I – Kardiologie, Angiologie und Internistische Intensivmedizin, Uniklinik RWTH Aachen, Aachen, Deutschland

    Nikolaus Marx

  2. Kardiologie, Pneumologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum Köln Klinik III für Innere Medizin, Köln, Deutschland

    Erland Erdmann

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Rassaf, T. (2023). Kardio-Onkologie. In: Marx, N., Erdmann, E. (eds) Klinische Kardiologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-62932-1_35

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-62932-1_35

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-62931-4

  • Online ISBN: 978-3-662-62932-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation